Breakthrough cases of COVID-19 infections in fully vaccinated patients are rising. The number of patients requiring supplemental oxygen and airway management, along with multiple therapies, including remdesivir, baricitinib, steroids, and antibiotics, is more than ever among the vaccinated group. Despite being fully vaccinated for SARS-CoV-2 earlier this year, some are getting hospitalized for COVID-19 possibly due to waning immunity. Few such patients decline for the worse requiring intubation as they have not received the SARS-CoV-2 booster dose yet. This case report showcases four fully vaccinated patients who get hospitalized for COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675596 | PMC |
| http://dx.doi.org/10.7759/cureus.19874 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seroprevalence of Diphtheria in Antananarivo, Madagascar, and Cambodia.
Open Forum Infect Dis
March 2025
Institut Pasteur Medical Center, Paris Cité University, Paris, France.
Background: Amidst a global resurgence of diphtheria cases with numerous outbreaks recorded worldwide since 2000, a better understanding of this vaccine-preventable disease's circulation is needed.
Methods: We retrospectively analyzed sera from 2 sero-epidemiological cross-sectional studies in Madagascar and Cambodia on fully primo-vaccinated 3- to 15-year-olds. Using enzyme-linked immunosorbent assay (ELISA) and seroneutralization (Vero Cell TNT) for the 3- to 8-year-olds with low ELISA titration values (<0.
Early Activation of Lung CD8 T Cells After Immunization with Live Malaria Sporozoites.
Pathog Immun
March 2025
Leiden University Centre for Infectious Diseases (LU-CID), Leiden University Medical Centre, The Netherlands.
Background: Two novel malaria vaccines, RTS,S and R21, mark a significant step forward in malaria research, but eradication demands vaccines with higher efficacy. Recent trials using late-arresting genetically attenuated parasites (LA-GAP) highlight their effectiveness as next-generation vaccines, likely through CD8 T-cell activation targeting late liver-stage parasites. However, the distribution of LA-GAP-activated T cells in different organs that culminate towards high-level protection in the liver remains unclear.
View Article and Find Full Text PDFEpidemiology and genetic diversity of classic human astrovirus with whole-genome sequence analysis in inpatient children under 5 years of age in Yunnan, China.
BMC Infect Dis
March 2025
Yunnan Provincial Key Laboratory of Public Health and Bisosafety & Institute for the Prevention and Control of Acute Infectious Diseases, Yunnan Center for Disease Control and Prevention (Yunnan Academy of Preventive Medicine), Kunming, China.
Purpose: The aim of this study was to determine the epidemiology, incidence and genetic diversity of classic human astrovirus (HAstV) in inpatient children under 5 years of age for acute gastroenteritis (AGE).
Methods: A hospital-based surveillance study was conducted across Yunnan Province to investigate the incidence of HAstV among AGE patients. Viral RNA was extracted from stool samples collected from January 2015 to December 2023 from hospitalized children under 5 years of age with AGE.
Immunogenic cross-reactivity between different serotypes novel duck reoviruses: Evaluation of cross-protection provided by mono or bivalent vaccine.
Poult Sci
February 2025
College of Veterinary Medicine, Gansu Agricultural University, Lanzhou, 730070, China. Electronic address:
To investigate the immunogenic cross-reactivity among different novel duck reovirus isolates, animals immunized with monovalent inactivated duck reovirus were challenged with homologous and heterologous viruses, and serum samples were collected after immunization for cross-neutralization test. The results showed that the virus neutralizing titer against homologous virus was significantly higher than that against heterologous virus(p < 0.000001), which indicated that there was an important difference in antigenicity between DE13 and WL01 strains, which affected the specificity of protective virus neutralizing antibodies induced.
View Article and Find Full Text PDFEffectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
Vaccine
March 2025
MRC/UVRI & LSTHM Uganda Research Unit, Entebbe, Uganda; London School of Hygiene & Tropical Medicine, London, UK.
Background: COVID-19 vaccines significantly reduce severe disease outcomes, but uncertainty remains about long-term protection. We investigated vaccine effectiveness (VE) against SARS-CoV-2 infection over extended periods in the World Health Organisation AFRO-MoVE network studies in Africa.
Methods: Participants with COVID-19-like symptoms were recruited between 2023 and 2024 for a test-negative case-control study conducted across 19-healthcare centres in Uganda.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!